MarketVIEW: HPV therapeutic vaccines

News provided by

Jan 08, 2014, 10:39 ET

LONDON, Jan. 8, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

MarketVIEW: HPV therapeutic vaccines

Human papilloma viruses (HPV) members of the papillomaviridae family are extremely common with an estimated worldwide prevalence of ~11-12%. Although nearly all sexually-active men and women acquire the virus at some point in their lives, most infections are asymptomatic and self-limiting; with 90% clearing within 2 years. High risk forms of HPV (16/18) can cause changes in the cells lining the mouth, throat or anogenital tract (including the cervix); called dysplasia and can lead to cancer. All (100%) of cervical cancers are thought to be caused by HPV which is thought to be responsible for 610,000 cancers worldwide.

Two prophylatic vaccines against HPV are currently licensed (Gardasil/Merck & Co & Cervarix/GSK Biologicals). Despite their deployment it is estimated it would take approximately 20 yrs from the implementation of mass vaccination for preventative vaccines to impact cervical cancer rates. In addition, in most HPV associated malignancies genomic integration of the virus has already occurred necessitating a different mechanism of action for a HPV therapeutic vaccine. Advaxis (Lovaxcin C) and ISA Pharmaceuticals (ISA101) are ongoing programs.

This MarketVIEW product is a comprehensive commercial opportunity assessment detailing the potential market for HPV therapeutic vaccine(s) using a patient based value/volume forecast for major Western markets to 2030. Two target product profiles (TPP) are forecasted targeting neoplasias: HPV16/18+ CIN, AIN, PIN, VIN & VAIN and HPV16/18+ established cancers - recurrent/persistent cervical cancer or oropharyngeal cancer. The analysis also includes an up-to-date review of epidemiology/guidelines/classifications, discussion of pricing considerations and an overview of current research and development in the field.

THIS PRODUCT IS COMPOSED OF SUMMARY PRESENTATION + 1 MODEL (optional)
Contents – Summary presentation (MS PowerPoint based)

Authors Note
Executive summary
HPV TX vaccine: potential revenues per indication (cancers) to 2030
HPV TX vaccine: potential volumes per indication (cancers) to 2030
HPV TX vaccine: potential revenues - cervical/per country to 2030
HPV TX vaccine: potential revenues - oral male/per country to 2030
HPV TX vaccine: potential revenues - oral female/per country to 2030
HPV TX vaccine: potential revenues - neoplasias to 2030
HPV TX vaccine: potential volumes per indication (neoplasias) to 2030
HPV TX vaccine: price sensitivity analysis (cancers)
Human papillomavirus: disease background
What is the human papillomavirus (HPV)?
Transmission of HPV and consequences of infection
Prevalence of HPV
Worldwide prevalence of HPV
The role of HPV in human cancers
Oncogenic mechanisms of HPV
HPV-related cancers
Population attributable fractions
HPV-related cancers divided by cancer type
5 year observed survival rate of HPV-related cancers
HPV-related cancers: disease background
Cervical cancer – background
Pathogenesis of cervical cancer
IARC meta-analysis of type-specific HPV DNA prevalence in invasive cervical cancer
Cervical cancer screening programmes
Cervical cancer screening - proportions of population screened
Cervical cancer and HPV prophylactic vaccines
HPV prophylactic vaccine schedules
Cervical cancer – incidence
Pre-cancerous cervical lesions
Incidence of pre-cancerous cervical lesions and attribution to HPV
Cervical cancer - current trends
Cervical cancer - outlook in the era of HPV prophylactic vaccination
Models predicting cancer incidence following HPV prophylactic vaccination
Oropharyngeal cancer – background
HPV-related oropharyngeal cancer - trends and epidemiology
Oropharyngeal cancer and HPV
HPV16 is the most prevalent type in oropharyngeal cancer
Oropharyngeal cancer - modelling considerations for therapeutic vaccine
Oropharyngeal cancer – incidence
Trends in oropharyngeal cancer incidence, cancers attributable to HPV and stage at diagnosis
Anal cancer – background
Anal cancer – incidence
Pre-cancerous anal lesions – incidence
Attribution of anal cancer and AIN to HPV and HPV type
Anal cancer – outlook
Penile cancer – background
Penile cancer – incidence
Pre-cancerous penile lesions – incidence
Outlook for pre-cancerous penile lesions
Vulvar cancer – background
Vulvar cancer – incidence
Pre-cancerous vulvar lesions – incidence
Outlook for vulvar cancer and pre-cancerous vulvar lesions
Vaginal cancer – background
Vaginal cancer – incidence
Pre-cancerous vaginal lesions – incidence
Outlook for vaginal cancers and VAIN
Treatment of HPV-related cancers: Current strategies
Current treatment of CIN and cervical carcinoma in situ
Current treatment of cervical cancer
Current treatment of oropharyngeal cancer
Treatment of other anogenital cancers
Human papillomavirus therapeutic vaccines: Overview of current R&D
The need for a HPV therapeutic vaccine
Therapeutic vaccine against HPV – background
Comparison of mechanism of action of prophylactic and therapeutic HPV vaccines
Examples of immune and clinical responses to HPV vaccines
Notable HPV therapeutic vaccines in current/past development
Ongoing HPV therapeutic vaccine trials on Clinicaltrials.gov
Ongoing HPV therapeutic vaccine trials: company reported
HPV therapeutic vaccines: summary of progress so far
Human papillomavirus therapeutic vaccines: Modeling commercial potential
Commercial considerations for a therapeutic HPV vaccine
Therapeutic HPV vaccine: target product profile (TPP)
Modelling strategy: indications and countries
Modelling strategy: populations/target groups
Model assumptions: incidence/prevalence of target precancerous lesions/cancers
Model assumptions: growth rates applied/precancerous lesions/cancers
Model assumptions: HPV 16/18+ prevalence within target precancerous lesions/cancers
Other indication specific model assumptions
HPV therapeutic vaccine (TX): model assumptions
Model assumptions: first dose HPV TX vaccine penetration rates
Model assumptions: 2nd/3rd/booster dose compliance rates
HPV TX vaccine (s): pricing considerations
Model validations (US): cancers
Model validations: PAP screening
Model validations: CIN
Model caveats and limitations
Bibliography
Disclaimer
About VacZine Analytics

PAGES: 118 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model(s) (MS Excel-based) – 1 model

Title sheet
CHARTS – cancers
CHARTS – neoplasias
Grand val vol sum – cancers
Grand val vol sum – neoplasias
Val summary – per indication
Val summary – cervical cancer
Val summary – oral cancer
Val summary – CIN
Val summary – PIN AIN
Val summary – VIN VAIN
Global pricing summary: Cancers
Global pricing summary: Neoplasias
Vol summary – per indication
Vol summary – cervical
Vol summary – oral cancer
Vol summary – CIN
Vol summary – PIN AIN
Vol summary – VIN VAIN
Cervical cancer worksheets
USA
UK
France
Germany
Italy
Spain
Canada
Australia
Japan
CIN1 & CIN2/3 worksheets
USA
UK
France
Germany
Italy
Spain
Canada
Australia
Japan
AIN2&3 worksheets
USA
M5EU
ROW
PIN worksheets
USA
M5EU
ROW
VIN worksheets
USA
M5EU
ROW
VAIN worksheets
USA
M5EU
ROW
Oropharyngeal cancer worksheets
USA
UK
France
Germany
Italy
Spain
Canada
Australia
Japan
Populations 20-65 yrs
Screening rates – Cervical
At risk variables
HIV prevalence
Backpage
WORKSHEETS: ~84

Read the full report:
MarketVIEW: HPV therapeutic vaccines
http://www.reportbuyer.com/pharma_healthcare/therapeutic/marketview_hpv_therapeutic_vaccines.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication